Apple has not released an Apple Watch with built‑in blood glucose monitoring, and as of June 2026, the U.S. Food and Drug Administration maintains that no smartwatch or smart ring on the market has been authorized to measure blood sugar noninvasively. The federal agency’s latest safety reminder lands amid a wave of unregulated wellness gadgets and persistent rumors that Apple is on the verge of cracking a decades‑old engineering puzzle.

For the 37 million Americans living with diabetes — and the roughly 96 million more with prediabetes — the promise of a wrist‑worn, needle‑free glucose monitor is tantalizing. Yet the FDA’s warning, first published in February 2024 and reiterated in subsequent communications, remains unambiguous: “Do not use smartwatches or smart rings to measure blood glucose. These devices have not been authorized, cleared, or approved by the FDA.” The agency cautions that inaccurate readings can lead to dangerously incorrect insulin doses and life‑threatening complications.

Meanwhile, Apple’s own health‑tech story has been one of incremental utility, not revolutionary leaps. The Apple Watch can display real‑time glucose data from FDA‑cleared continuous glucose monitors (CGMs) like the Dexcom G7 or Abbott’s FreeStyle Libre, but it stops at being a passive viewer. You still need a sensor under your skin, a transmitter, and a dedicated mobile app. The watch merely mirrors numbers that have already been validated elsewhere.

How CGMs Work with Apple Watch Today

Apple’s HealthKit and WatchOS provide robust APIs that let third‑party developers stream CGM data directly to the wrist. Dexcom’s G7 app, for example, was updated in 2025 to offer a native Apple Watch complication, showing current glucose, trend arrows, and 3‑hour history without requiring the phone nearby. Setup requires a paired iPhone for initial configuration, but once running, the watch can operate independently as long as it has a Bluetooth connection to the CGM transmitter.

Abbott followed suit with a FreeStyle Libre 3 watchOS app in late 2025, though initially limited to European markets. Both apps must navigate FDA‑defined “secondary display” regulations, meaning they cannot replace the primary medical device, and their readings should not be used for treatment decisions without confirming with a fingerstick or the original receiver.

These integrations are clever but far from a native solution. Users still face the daily realities of sensor insertion, adhesives, warm‑up periods, and the occasional pressure‑low false alarm that wakes them at 3 a.m. The watch merely becomes a more convenient screen — an extension, not a replacement.

The FDA’s Bright Line

Why can’t Apple or any competitor just ship a noninvasive glucose sensor? The FDA’s regulatory framework for blood‑glucose monitoring devices is among the strictest in the consumer‑electronics world. Any device that claims to measure blood glucose — whether it uses optical spectroscopy, infrared light, or bioimpedance — must demonstrate safety and effectiveness through premarket approval (PMA) or 510(k) clearance, including rigorous clinical trials that compare its readings against gold‑standard lab tests.

So far, no noninvasive technology has met that bar. The FDA has never cleared a smartwatch or smart ring to estimate blood glucose. Devices that make such claims — often sold on crowdfunding platforms or direct‑to‑consumer websites — either skirt regulation by calling themselves “wellness” or “lifestyle” products, or they flat‑out lie. The FDA’s 2024 safety communication specifically cautioned that “sellers of these devices are marketing them to consumers with diabetes, but the devices could cause serious harm.”

That stark warning hasn’t killed curiosity. A 2025 review by the Journal of Diabetes Science and Technology found over 200 wearable products claiming glucose tracking, the overwhelming majority of which had no medical certification. Many relied on algorithms processing heart‑rate variability or galvanic skin response, metrics that can correlate weakly with blood sugar but are insufficiently precise for clinical dosing decisions.

Apple’s Quiet Noninvasive Pursuit

Apple’s interest in noninvasive glucose monitoring is one of the worst‑kept secrets in Silicon Valley. Reports from Bloomberg, The Information, and other outlets have detailed an internal project — sometimes referred to as “E5” or “Project Mudra” — that aims to measure blood glucose using a technique called silicon photonics. The idea is to shine a laser through the skin into the interstitial fluid and analyze the reflected light spectrum, deriving a glucose concentration without breaking the skin.

The project has reportedly been in the works for over a decade, involving hundreds of engineers and a dedicated facility in Cupertino. Key figures like Apple’s senior director of health technologies have filed multiple patents covering optical sensors, algorithms, and thermal management for a compact wrist‑worn device. One 2024 patent describes a “multi‑wavelength photoplethysmography” system that attempts to distinguish glucose from other blood constituents like hemoglobin and water.

Despite the investment and IP, the technical hurdles remain monumental. Skin color, ambient temperature, sweat, motion artifacts, and even the thickness of the epidermis can throw off optical measurements. “You’re trying to detect a needle in a haystack while the haystack is moving and changing color,” one biomedical engineering professor told MedTech Dive in 2025. The sensor must contend with a signal‑to‑noise ratio where glucose contributes less than 0.1% of the total light absorption — a challenge that has thwarted academic labs and startups for decades.

In June 2026, Apple had not announced a release date or even a feasibility proof for a standalone glucose‑sensing Watch. Company spokespeople, when asked during quarterly calls, pivot to the broader health‑tracking narrative: atrial fibrillation detection, sleep apnea notifications, and the FDA‑cleared ECG app. Tim Cook’s famous 2023 comment that he wears a CGM to better understand his own glucose levels was interpreted by many as a hint, but Apple later clarified that it was a personal health experiment, not a product preview.

The Competitive Landscape

Apple isn’t alone in chasing the dream. Samsung and Google (via Fitbit) have publicly announced research programs exploring noninvasive glucose monitoring. Samsung’s 2024 Galaxy Unpacked keynote teased a “BioActive Sensor” that could one day add “glucose trend monitoring.” Google’s 2023 acquisition of a small startup working on radio‑frequency spectroscopy signaled its intent, though the team was folded into the health division and has not produced a consumer product.

Smaller players have tried — and often failed — to fill the gap. Rockley Photonics, a supplier that once counted Apple as its largest customer, filed for bankruptcy in 2023 after its wrist‑worn “clinic‑on‑the‑wrist” module failed to gain traction. The company’s technology could measure core body temperature, hydration, and alcohol, but glucose remained elusive. H2O.ai and Scanadu are other names that burned through venture capital before dissolving.

Wearable glucose monitoring remains dominated by traditional CGM manufacturers. Dexcom and Abbott collectively generate over $10 billion in annual revenue from sensor‑based systems that pierce the skin. While their sensors are minimally invasive, they still require a filament under the skin — a dealbreaker for many potential users who fear needles or suffer from adhesive allergies.

When Could a Noninvasive Apple Watch Arrive?

Predictions range from “this year” to “never.” Analyst Ming‑Chi Kuo, known for accurate Apple supply‑chain forecasts, suggested in a 2024 note that the glucose sensor was “at least three to five years away from commercial viability.” Others, like Bloomberg’s Mark Gurman, have reported that the project has moved from “waterfall” to “incremental” mode, where the core science is considered proven but miniaturization and reliability remain works‑in‑progress.

The most optimistic scenario sees Apple announcing a glucose‑sensing Watch alongside a new generation of health services. The device might not give a precise mg/dL number but instead categorize readings into “normal,” “elevated,” or “low” — similar to how the Apple Watch’s blood‑oxygen app offers a percentage reading without claiming the precision of a medical pulse oximeter. Such a “wellness” feature could skirt the FDA’s strictest requirements while still requiring FDA clearance for a “general wellness” claim. This path was opened by the FDA’s 2019 General Wellness Policy, which exempts low‑risk devices that promote a healthy lifestyle without diagnosing or treating disease.

But even a wellness‑oriented glucose tracker must be accurate enough to avoid false alarms. If a watch incorrectly suggests a user is hypoglycemic, the psychological stress alone could drive unnecessary emergency visits. Consumer expectations, shaped by the life‑or‑death nature of diabetes management, demand near‑clinical precision.

The Real‑World Impact of FDA inaction

While Apple waits, patients are cobbling together their own DIY solutions. A robust online community called “Nightscout” has for years enabled cloud‑based CGM data sharing to smartwatches, including the Apple Watch, through web browsers and custom complications. Others use shortcuts and scripts to scrape glucose values from companion phone apps and display them in a corner of their wrist.

These workarounds illustrate the market’s appetite — and the risk. A 2025 survey by the diabetes nonprofit Tidepool found that 41% of CGM users would strongly consider switching to a noninvasive watch if it were available, even if slightly less accurate. Nearly a third of respondents said they already rely on their smartwatch as their primary glucose display, occasionally skipping fingerstick confirmations.

That behavioral shift concerns endocrinologists. “We’re seeing patients who trust their watch more than their CGM receiver,” said Dr. Anne Peters, a UCLA diabetes specialist, during a 2026 ADA conference panel. “When the watch shows a value that doesn’t match how they feel, they sometimes ignore symptoms because the watch looks authoritative. That’s dangerous.”

Privacy and Data Ownership

Any Apple glucose solution will also wade into the murky waters of health data privacy. The Apple Watch already collects a detailed picture of a user’s health — heart rate variability, blood oxygen, sleep stages, and activity patterns. Adding glucose data, especially continuous readings, would create a digital phenotype that insurers, employers, or advertisers might covet.

Apple has historically positioned itself as a privacy champion, storing health data encrypted on‑device and not selling it. But the company’s growing interest in healthcare partnerships — such as its 2025 collaboration with Elevance Health to offer Apple Watch‑based wellness incentives — raises questions about how glucose data might flow. Even anonymized, aggregated glucose trends could be commercially valuable to food companies, pharmaceutical firms, or public health agencies.

Federal and state regulators are watching. California’s Consumer Privacy Act and the EU’s GDPR impose strict rules on health data, and the FTC has signaled it may treat glucose readings as sensitive biometric information. If Apple ever ships a sensor, it will need to navigate a global patchwork of regulations while maintaining its privacy promises.

What Windows Users Should Care About

It might seem odd for a Windows‑focused outlet to delve into Apple Watch minutiae, but the glucose saga matters far beyond the Apple ecosystem. First, Microsoft’s health‑tech ambitions — expressed through Microsoft HealthVault, the now‑defunct Microsoft Band, and current cloud‑based healthcare solutions — are directly shaped by what Apple and Google achieve. If Apple solves noninvasive glucose, it will create a template for sensor‑based health monitoring that every platform, including Windows, must support. Today, CGM data flows through browser‑based interfaces that work on any OS; tomorrow, a proprietary Apple API could shift that balance.

Second, the healthcare industry runs on Windows. Clinics, hospitals, and insurance companies rely on Windows workstations to manage patient data. When a patient walks in wearing a smartwatch that claims to measure glucose, the IT infrastructure must eventually incorporate that data stream into electronic health records (EHRs). Epic and Cerner, the dominant EHR platforms (both run on Windows servers), have already built APIs for patient‑generated health data. A widely adopted noninvasive sensor would accelerate the need for seamless integration — and Windows‑based systems would need to handle the load.

The Unsolved Noninvasive Challenge

Decades of research have explored a dozen noninvasive pathways: near‑infrared spectroscopy, Raman spectroscopy, polarized light, radio‑wave impedance, thermal emission, and even tears or saliva analysis. Each technique runs into hurdles. Optical methods struggle with interference from water, proteins, and melanin. Impedance methods cannot distinguish glucose from other electrolytes. Tears and saliva resist calibration because glucose concentrations there lag blood levels by 15‑30 minutes.

Google’s infamous 2014 smart‑contact‑lens project, which aimed to measure glucose in tears, was abandoned in 2018 after the company concluded the correlation was too weak. The effort, while well‑funded and staffed, highlighted a perennial truth: biological noise often overwhelms the signal.

Apple’s silicon‑photonics approach may be the most sophisticated attempt yet, but even if the sensor works in a lab, manufacturing it at scale inside a consumer watch is another order of difficulty. The laser sources must be eye‑safe and power‑efficient enough to run all day without draining the battery. The optics need a clear, sweat‑resistant window that does not fog or scratch. Algorithms must compensate for skin tone, blood perfusion, and motion, all while respecting on‑device processing constraints.

The Road Ahead

The FDA’s consistent position has not changed: no watch has been cleared to measure blood glucose. Until that changes, the safest option for people who need glucose data is a proven CGM system, whose readings can be mirrored on an Apple Watch or any smart device with the appropriate app. Apple’s role, for now, is that of a premium data dashboard, not a diagnostic tool.

Looking forward, the next major milestone may come not from a product launch but from a pivotal study. If Apple submits a de novo classification request to the FDA with clinical data showing its noninvasive sensor matches CGM accuracy, that filing itself would be news. Rumors of such a submission surfaced briefly in 2025 but were never substantiated. Should it happen, the review process alone could take 12‑18 months, pushing any theoretical release into 2027 or beyond.

In the meantime, Apple Watch users will have to make do with the FDA‑cleared apps that already exist — and resist the temptation to trust unregulated devices that promise miracles on a wrist.